RE: Tier 2 Lockdown: midnight today - Last chance to get in16 Oct 2020 16:44
I lile your posts wise_buys, this from the August was also a very good post.
Over the past months, I’ve seen some comments stating that 300p is not likely, those are clearly from new investors who have invested only this year. These investors probably did not know Genedrive were once called EpiStem, whom first listed at 124p a share (SP just above 90p now). However, like most diagnostic, pharma, medical and biotech companies, there is a huge decrease in SP over the years, until they meet their milestones.
Genedrive was trading over 500p in 2014 and 300p less than 5 years ago. I’ve been in Genedrive for some time now, added in mid-April 2020, May 2020 and this week. I’ve seen the ups and downs of the SP, and seen many impatient investors/traders panicking and selling.
For the new investors who seem to be excited (yet anxious) about only the covid tests, consider the following points:
1. Genedrive has more than one product.
2. Covid statistics show that it is not going away. The supply for testing worldwide is less than the demand. All companies producing covid tests with great partners will benefit, Genedrive is in this category.
3. Genedrive are working with the US Department of Defence and already have FDA approved products. I’m confident their first covid test will receive approvals in all countries, especially FDA approval (already achieved CE marking, which at the time investors were doubting). The covid test is produced by Cytiva, whom have operations in the US, and also have produced many FDA approved products in the past.
4. FDA approval is likely to drop anytime between now and in two weeks.
5. The Beckman deal shows huge potential.
6. Genedrive at a £50m market cap is tiny, this could easily be over £150m market cap (300p stock), compare them to their UK peers.
We need more people like this guy.
Sign In
Follow the stocks
